Prediction of serum M30 and M65 levels for the short-term prognosis of patients with hepatith B virus related acute-on-chronic liver failure during artificial liver support system therapy / 中华传染病杂志

ABSTRACT

The levels of M30 and M65 in the improvement group,non-recovered group and control group were significantly different before the first ALSS therapy(F=109.36 and 90.42,respectively,both P＜0.01).The levels of M30 and M65 were not significantly different between improvement group and non-recovered group before treatment(t=0.836 and 0.286,respectively,both P＞0.05).However,after twice ALSS therapy,the levels of M30 and M65 in non-recovered group were significantly higher than those in improvement group(t=30.699 and 64.777,respectively,both P＜0.01).Moreover,after the second ALSS therapy,the levels of M30 and M65 were both significantly lower compared to those after the first-time therapy in the improvement group(t=3.350 and 5.932,respectively,both P＜0.01).The areas under Curve(AUC)of M30,M65 and the combination of M30 and M65 for prognosis prediction were 0.796,0.844 and 0.906,respectively.The AUC of combination of M30 and M65 was significantly higher than M30 or M65 alone(Z=2.163 and 2.141,respectively,P=0.031 and 0.032,respectively).The cut-off values of M30 and M65 were 591.91 and 924.50 U/L,respectively.The sensitivity and specificity of combined M30 and M65 were 94.7％and 82.5％,respectively.Conclusions Serum M30 and M65 levels can predict the short-term prognosis of HBV-ACLF patients after ALSS therapy.The combination of M30 and M65 is of better diagnostic value.